8-K: NewAmsterdam Pharma Highlights 2025, Eyes 2026 Milestones

NewAmsterdam Pharma reported approximately $729 million in cash, cash equivalents, and marketable securities as of December 31, 2025, while outlining key clinical development progress and strategic priorities for 2026.

Summary

• Unaudited cash, cash equivalents, and marketable securities balance was approximately $729 million as of December 31, 2025.
• An EMA approval decision for obicetrapib monotherapy and fixed-dose combination with ezetimibe is expected in the second half of 2026.
• The Phase 3 PREVAIL cardiovascular outcomes trial (CVOT) overall event rate is tracking in line with the observed rate in the Phase 3 BROADWAY trial.
• The first patient was enrolled in the RUBENS Phase 3 trial in December 2025, evaluating obicetrapib in patients with type 2 diabetes or metabolic syndrome, with topline results expected by year-end 2026.
• Positive data from a prespecified Alzheimer's disease (AD) biomarker analysis in the BROADWAY trial showed statistically significant reductions in p-tau217, a key AD biomarker, in both the full analysis set (p<0.002, n=1,515) and ApoE4 carriers (p=0.0215, n=367).
• The company plans to initiate its first dedicated Alzheimer's trial in 2026 based on the positive biomarker data.
• Pooled efficacy and safety data from pivotal Phase 3 BROADWAY and BROOKLYN trials were presented at ESC 2025 and published in the Journal of the American College of Cardiology.
• Marketing Authorization Applications (MAAs) for obicetrapib were accepted for review by the EMA in August 2025, submitted by partner Menarini.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, highlighting significant clinical and regulatory progress for obicetrapib, a strong cash position sufficient for key milestones, and expansion into a new therapeutic area (Alzheimer's disease). The tone is confident and forward-looking, with no explicit negatives or delays mentioned.

Positives

• Strong unaudited cash, cash equivalents, and marketable securities balance of approximately $729 million as of December 31, 2025, sufficient to fund operations through PREVAIL CVOT readout and subsequent US commercial launch, if approved.
• EMA approval decision for obicetrapib and its fixed-dose combination expected in 2H26, indicating significant regulatory progress in Europe.
• The PREVAIL CVOT overall event rate is tracking in line with expectations, suggesting positive progress in this critical trial.
• Initiation of the RUBENS Phase 3 trial expands the potential label for obicetrapib to patients with Type 2 Diabetes and/or Metabolic Syndrome.
• Statistically significant reductions in p-tau217, a key Alzheimer's disease biomarker, observed in the BROADWAY trial, supporting an emerging link between CETP-inhibition and neurodegeneration.
• Plans to start a dedicated Alzheimer's trial in 2026, diversifying the pipeline and exploring new therapeutic areas.
• Acceptance of Marketing Authorization Applications (MAAs) by the EMA for review, demonstrating advancement towards European commercialization.

Risks

• Uncertainties and delays regarding the initiation, enrollment, and completion of clinical trials.
• Uncertainties regarding the outcome of clinical trials and whether results will be adequate to support regulatory review and approval.
• Topline, initial, or preliminary results from clinical trials may not be predictive of final results or indicative of later trials.
• Potential for varying interpretations of clinical trial results and analyses.
• Risks related to the ability to achieve business plans, objectives, and milestones, including product approval and commercialization.
• Unanticipated costs and expenses could impact the company's cash runway.
• Ability to source raw materials for product candidates and ensure adequate supply for clinical trials and commercialization.
• Impact of competing product candidates on the company's business.
• Risks and uncertainties relating to intellectual property and regulatory exclusivities.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.

Future Outlook

The company anticipates an EMA approval decision for obicetrapib and its fixed-dose combination in the second half of 2026, with preparations for a potential commercial launch in Europe. The PREVAIL CVOT is tracking as expected, and the RUBENS trial is projected to yield topline data by year-end 2026. Enrollment for the REMBRANDT trial is expected to complete in 2026. Furthermore, the company plans to initiate its first dedicated Alzheimer's trial in 2026 and continues to develop a portfolio of obicetrapib-based combinations.

Management Comments

• "2025 was an important year for NewAmsterdam, as we continued to further the regulatory process for obicetrapib and the fixed-dose combo."
• "In partnership with Menarini, the company is preparing for a potential commercial launch in Europe, contingent upon an EMA approval decision that is expected in 2H26."
• "In PREVAIL, we are encouraged by the rate of overall MACE events (blinded) in this cardiovascular outcomes trial (CVOT), which suggest that the initial 12 month rate is tracking in line with the overall rate observed in the Phase 3 BROADWAY trial."
• "We are also excited to announce the RUBENS trial enrolled its first few patients in December and could allow for additional label enhancements, if approved, for patients with Type 2 Diabetes and/or Metabolic Syndrome that are not at their LDL-C risk-based goals. We expect topline results from the trial by the end of 2026."
• "As we look to 2026, we remain committed to advancing our broader clinical development strategy, which includes three Phase 3 trials, PREVAIL, REMBRANDT, and RUBENS."
• "In addition and based on the positive data from our Alzheimers disease (AD) biomarker analysis from the BROADWAY trial, we are planning to start our first dedicated Alzheimers trial in 2026."
• "This study could further demonstrate the potential of obicetrapib to modify key biomarkers and clinical pathology of AD."
• "Lastly, we continue to make progress towards building out a portfolio of obicetrapib based combinations, conducting studies that could guide the development of proprietary fixed-dosed combinations in the future."

Industry Context

Cardiovascular disease remains the leading cause of death globally, with over 184 million U.S. adults expected to be affected by CVD and hypertension by 2050. Despite the availability of lipid-lowering therapies (LLTs), LDL-C target level attainment remains low, contributing to significant residual cardiovascular risk. Approximately 30 million under-treated U.S. adults are not at their risk-based LDL-C goal, and 10 million patients with elevated LDL-C are not taking any LLTs, highlighting a substantial unmet clinical need for improved therapeutic regimens like obicetrapib.

Comparison to Industry Standards

• Current lipid-lowering therapies (LLTs), including high-intensity statins, are not sufficiently effective or well-tolerated for many patients at risk of cardiovascular disease with elevated LDL-C.
• Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL, and only 10% of very high-risk ASCVD patients achieve the goal below 55 mg/dL, indicating a significant gap in current treatment efficacy.
• Obicetrapib is being developed as a preferred LDL-C lowering therapy to be used as an adjunct to statin therapy, aiming to address the limitations of existing treatments and the large population of under-treated patients.

Stakeholder Impact

• Shareholders: Potential for increased value through successful clinical development, regulatory approvals, and commercialization of obicetrapib, as well as expansion into new therapeutic areas like Alzheimer's disease.
• Patients: Development of new, potentially more effective and well-tolerated oral therapies for cardiovascular disease and potentially Alzheimer's disease, addressing significant unmet medical needs.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline and commercialization efforts.
• Partners (Menarini): Continued collaboration and potential for commercial success in Europe based on EMA approval and market penetration.

Next Steps

• Receive EMA approval decision for obicetrapib and obicetrapib/ezetimibe fixed dose combination in 2H26.
• Prepare for potential commercial launch in Europe, contingent upon EMA approval.
• Announce additional data from the BROADWAY, TANDEM, and BROOKLYN trials.
• Complete enrollment of approximately 300 patients in the REMBRANDT Phase 3 trial in 2026.
• Obtain topline data from the RUBENS Phase 3 trial by year-end 2026.
• Initiate a new clinical trial evaluating obicetrapib in early Alzheimer's disease patients in 2026.
• Continue progress towards building out a portfolio of obicetrapib-based combinations.

Key Dates

Recommendation

The company demonstrates strong operational execution with significant clinical trial progress, including positive biomarker data for Alzheimer's disease and ongoing late-stage cardiovascular trials. The substantial cash balance of $729 million provides a robust runway through critical milestones, including a potential US commercial launch. Regulatory progress in Europe with EMA MAA acceptance further de-risks the commercialization pathway. The expansion into Alzheimer's disease represents a promising diversification of the pipeline. These factors collectively indicate strong growth potential and a favorable risk-reward profile for long-term investors.

Keywords

Obicetrapib, CETP inhibitor, LDL-C, Cardiovascular Disease, Alzheimer's Disease, Clinical Trials, Phase 3, PREVAIL, RUBENS, REMBRANDT, EMA approval, Biopharmaceutical, Hypercholesterolemia, Metabolic Syndrome, Cash Balance